Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (March 2023)
20 slides from Shuttle Pharmaceuticals's investor presentation, Mar 22, 2023
Slide 1: Shuttle Pharmaceuticals Investor Presentation March 2023
Shuttle Pharmaceuticals, Inc. Nasdaq: SHPH ase Investor Presentation Ssoas Babe ae BARENACEUTICALS March 2023.
Slide 2: Disclaimers
Disclaimers Forward Looking Statements All of the information contained within this business plan presentation (the “Presentation’) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle” o
Slide 3: Experts in Radiation Oncology
Experts in Radiation Oncology = Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior management and academic positions including Prior to co-founding Shuttle, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became public as NeoPharm, Inc. (Nasdaq:
Slide 4: Company Overview
Company Overview = Shuttle Pharma (Nasdaq: SHPH) is a clini oncology solutions for combined mod radiation sensitizing drugs = Mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of Radiation Therapy (RT) while limiting the late e
Slide 5: The Fundamental Problem Facing Radiation Therapy
The Fundamental Problem Facing Radiation Therapy Cancers are surrounded by radiation sensitive normal tissues that limit the maximum treatment dose Strategies to overcome cancer resistance to radiation therapy: ™ Sensitize Cancer Cells To Radiation Therapy = Radiation sensitizers improve cancer cont
Slide 6: Lead Drug Candidates
Lead Drug Candidates Objective is to improve the outcomes of cancer treatment through RT while reducing its side effects by: = Sensitizing growing cancer cells to render them more susceptible to the effects of RT; " Activating the DNA damage response pathway to protect normal cells located near canc
Slide 7: Competitive Landscape
Competitive Landscape Side-effects Tot. Revenue (est.) “OFF-LABEL” Sensitizer Used 5-Flourouracil = Colon and rectal cancer + Enteritis . BE (Adruc * Breast Cancer + Transient lymphocytopenia $19 milion with Radiation Therapy tent expiry: 19) = Pancreatic cancer + Nausea . Capecitabine = Colon and r
Slide 8: Market Opportunity
Market Opportunity Immuno-therapies and radiation sensitizers are expected to improve outcomes in many cancers ~ 1.8 M new cancer cases annually in the U.S. ~ 450,000 patients with local/regional cancers are candidates for RT with sensitizers ~ “Off-label” use of radiation sensitizing drugs predomin
Slide 9: Clinical Pipeline
Clinical Pipeline Pipeline composed of two parts: Ropidoxuridine, our lead cli cancer cells and, various selective HDAC (histone deacetylase) immune system. ical drug candidate, w! itors — which sen: h sensitizes rapidly growing e cancer cells and stimulate the Next Anticipated Pre-clinical Phase 1
Slide 10: Ropidoxuridine Platform: Overview
Ropidoxuridine Platform: Overview ® Ropidoxuridine (IPdR) is an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties. ® Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and the cells become more sensitive to the effects of RT. ®
Slide 11: Ropidoxuridine Platform: Clinical Studies
Ropidoxuridine Platform: Clinical Studies = Ropidoxuridine (IPdR) is the prodrug of IUGR = IUAR is a powerful radiation sensitizer showing Phase Il efficacy in NIH sponsored clinical trials = IUGR and RT for sarcoma patients resulted in improved survival = IUGR and RT for glioblastoma and anaplastic
Slide 12: Ropidoxuridine Platform: Recent Activities
Ropidoxuridine Platform: Recent Activities Manufacturing Agreement - TCG GreenChem ® In September 2022, the Company announced an agreement with TCG GreenChem, Inc. to manufacture Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in clinical trials of Ropidoxuridine and R
Slide 13: Ropidoxuridine Platform: Next Steps
Ropidoxuridine Platform: Next Steps = Develop Ropidoxuridine (IPdR) for Orphan disease indications to take to market = Manufacture 24 kg of Ropidoxuridine and formulate for use in clinical trials. * Conduct a Phase II clinical trial of Ropidoxuridine, Temodar and RT in glioblastoma. ® Conduct a Phas
Slide 14: HDAC Inhibitor Platform: Overview
HDAC Inhibitor Platform: Overview = The company has discovered novel HDAC inhibitor molecules and testing in preclinical models has shown cancer radiation sensitizing properties, normal tissue protective properties and selective HDAC6 inhibitory properties. = Our HDAC inhibitor platform will be eval
Slide 15: HDAC Inhibitor Platform: SP-2-225 Immuno-activator and HDAC6 Target
HDAC Inhibitor Platform: SP-2-225 Immuno-activator and HDAC6 Target Targeting HDAC6 for SM1 melanoma tumor growth inhibition Surface Expression of MHC 1+ SIINFEKL 3000 * Vehicle 4 225 (25 mg/kg) 26: mur 2500 2 mrt 2 = mm 225 £2000 34s 2 . g mm 225¢RT § 150 < 3 Z 10 S z . 21001 & 08 e 500 a sé ¢& Day
Slide 16: Intellectual Property Portfolio for Radiation Sensitizers
Intellectual Property Portfolio for Radiation Sensitizers fellectual property for Ropidoxuridine includes novel formulations that show improved drug bioavailability (in a preclinical animal model) and for sensitizing cancers to proton and to conventional radiation therapies. = Our HDAC inhibitor int
Slide 17: Summary: Clinical Development Strategy for Radiation Sensitizers
Summary: Clinical Development Strategy for Radiation Sensitizers = Shuttle Pharma has a broad pipeline to improve clinical outcomes of patients treated with radiation therapy for cancer = Priority #4: Advance Ropidoxuridine & RT to treat brain tumors (glioblastoma) ™ Capitalize on Ropidoxuridine as
Slide 18: Financial Overview
Financial Overview Company believes it has sufficient capital to fund operations into the 4th quarter of 2025, which will allow for the advancement of Ropidoxuridine and its HDAC inhibitors to reach additional important milestones. Shuttle Pharmaceuticals Cap Table as of December 31, 2022 Capital Ma
Slide 19: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team Anatoly Dritschilo, MD CEO & Chairman, Tyvin Rich, MD Medical Director Founder & CEO of Shuttle Pharma since 2012. Chairman, Board of Directors 2017 Member, Board of Directors, = Served as President & COO of Shuttle Pharma since 2012 = MBA George Neopharm inc. 1
Slide 20: Thank You
THANK YOU PHARMACEUTICALS. Anatoly Dritschilo, MD CEO, Shuttle Pharmaceuticals Holdings, Inc. Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org
Shuttle Pharmaceuticals Holdings — Investor Presentation (March 2023) on 6ix